Photo of Dr Anjali Rampersad

Dr Anjali Rampersad

Telephone:

Location:

  • University College Hospital

GMC/GDC number:

7482466

Professional background

Dr Rampersad is a dual qualified paediatric allergist and general paediatrician. She completed her paediatric allergy subspeciality training in London across four different tertiary centres including Evelina London Children’s Hospital, Great Ormond Street Hospital for Children, Royal London Hospital and Kings College Hospital.

She is a part of national allergy committees such as the British Society of Paediatric Allergy and Immunology Paediatric Allergy Committee and Adolescents and Young Adult Working group.

She is passionate about reducing disparities in allergy provision and improving allergy education and awareness.

Specialties

Research interests

  • Paediatric allergy
  • Food allergy 
  • Food immunotherapy 
  • Atopic dermatitis
  • Allergy transition 
  • Allergic rhinitis

Languages spoken

Learning German and Spanish

Publications

  • Rampersad A, Brough H. The Nuts and Bolts of Early Peanut Reintroduction. JACI-IP, 2024. 12-12. https://doi.org/10.1016/j.jaip.2024.09.027
  • Rampersad A, Gholam K, Solman L, Cartledge N et al. Dupilumab-related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London. JEADV Clin Pract. 2024; 1–6. DOI: 10.1002/jvc2.528
  • Marrs T, Patel N, Burrell S, Rampersad A et al. BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study. Clin Exp Allergy. 2024; 54: 459-469. DOI: 10.1111/cea.14491
  • Rampersad A, Siddiqui F, Qiyu M, Traves D et al. Allergen immunotherapy in the UK: what's new? Paediatrics and Child Health, Volume 34, Issue 6, 186 – 192. DOI: 10.1016/j.paed.2024.03.002
  • Rampersad A, Gholam K, Solman L, Cartledge N et al. P31 Eyeing up: dupilumab-associated ocular surface disease in children with eczema in a tertiary paediatric hospital in London, British Journal of Dermatology, 2023; 189, Issue 3, 52-53. DOI:10.1093/bjd/ljad259.039
  • Rampersad A, Banerjee N, Hinks TSC. Are biologics for chronic rhinosinusitis effective and safe? Clin Exp Allergy. 2021; 51: 870– 872. DOI: 10.1111/cea.13904
  • Harnik E, Lee R, Rampersad A. Best of the other journals. Clin Exp Allergy. 2021 Mar,51(3):509. DOI:10.1111/cea.13806
  • Harnik, E., Lee, R. and Rampersad, A. (2021), Best of the other journals. Clin Exp Allergy, 51: 509-509. DOI: 10.1111/cea.13851